Prevalence of PD-L1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.
In this study of 118,187 tumor samples from a de-identified database, including a subset of 2039 samples from a clinically annotated database, the prevalence of PD-L1 amplification was 0.7%. The objective response rate for patients with solid tumors that harbored PD-L1 amplification was 66.7%, with a median progression-free survival of 15.2 months. The results of this […]
